Skip to content
ppharmaranks
Menu
Class IIOngoing

DULOXETINE D/R recall

FDA recall D-0617-2026 · initiated Jun 22, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 1, 2026How we research

Direct Rx recalled DULOXETINE D/R in Jun 2026 — an FDA Class II recall (D-0617-2026) because CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.

Quantity recalled: 263 Bottles

Details

Product
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Recalling company
Direct Rx
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
U.S. Nationwide
Initiated
Jun 22, 2026
FDA report date
Jul 1, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was DULOXETINE D/R recalled?
Direct Rx recalled DULOXETINE D/R in Jun 2026 — an FDA Class II recall (D-0617-2026) because CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. May cause temporary or medically reversible harm; low probability of serious harm.
Why was DULOXETINE D/R recalled?
Per the FDA enforcement record, the reason for recall D-0617-2026 was: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Is a recalled DULOXETINE D/R dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of DULOXETINE D/R are affected?
Distributed: U.S. Nationwide. The recall covers these lots — Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0617-2026.

Source: openFDA Drug Enforcement record D-0617-2026

← All drug recalls